Request Demo
Last update 21 Mar 2025
Amivantamab-VMJM/Hyaluronidase
Last update 21 Mar 2025
Overview
Basic Info
Drug Type Bispecific antibody, Enzyme |
Synonyms- |
Action antagonists, modulators, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Hyaluronic acid modulators, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 143885L
The sequence is quoted from: *****
Sequence Code 13387733H
The sequence is quoted from: *****
Sequence Code 13387743H
The sequence is quoted from: *****
Sequence Code 13387747L
The sequence is quoted from: *****
Sequence Code 453129440
The sequence is quoted from: *****
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | NDA/BLA | United States | 17 Jun 2024 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Japan | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Argentina | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Brazil | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Canada | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | France | 05 Aug 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Germany | 05 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free